Brink's Receives CMA Acceptance in Principle of Proposed Remedy Relating to Pending Acquisition of NCR Atleos

Impact · against what's priced in

Brink's has cleared a significant regulatory hurdle in the UK, reducing the risk of a Phase 2 investigation and keeping the NCR Atleos acquisition on track for Q1 2027. Because the divestiture of NoteMachine/TestLink UK does not impact the projected $200 million in cost synergies, the financial upside of the deal remains intact.

BCO+0.60: No priced-in read yet

Brink's Receives CMA Acceptance in Principle of Proposed Remedy Relating to Pending Acquisition of NCR Atleos

What matters in this story

Movado Group, Inc. Enters Into Agreement to Sell Majority Interest in EBEL

Brink's Receives CMA Acceptance in Principle of Proposed Remedy Relating to Pending Acquisition of NCR Atleos

What matters in this story

Movado Group, Inc. Enters Into Agreement to Sell Majority Interest in EBEL

How each ticker is affected

Connected tickers

Track these names every morning.

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Busy Q3 Sets Up United Community Banks For Improved Results

Market Concentration Is Spooking Wall Street—I'm Buying Kenvue

Regions Financial Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Brink's Receives CMA Acceptance in Principle of Proposed Remedy Relating to Pending Acquisition of NCR Atleos

What matters in this story

Next reads from the same story arc

Movado Group, Inc. Enters Into Agreement to Sell Majority Interest in EBEL

Brink's Receives CMA Acceptance in Principle of Proposed Remedy Relating to Pending Acquisition of NCR Atleos

What matters in this story

Next reads from the same story arc

Movado Group, Inc. Enters Into Agreement to Sell Majority Interest in EBEL

How each ticker is affected

Connected tickers

Track these names every morning.

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Busy Q3 Sets Up United Community Banks For Improved Results

Market Concentration Is Spooking Wall Street—I'm Buying Kenvue

Regions Financial Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call